Neurocrine Biosciences, Inc. (NBIX)
USD 109.68
(2.9%)
USD 109.68
(2.9%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 428.4 Million USD | 62.95% |
| 2022 | 262.9 Million USD | -40.3% |
| 2021 | 440.4 Million USD | 6.82% |
| 2020 | 412.3 Million USD | -16.79% |
| 2019 | 495.5 Million USD | 27.54% |
| 2018 | 388.49 Million USD | 5.11% |
| 2017 | 369.61 Million USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 11.53 Million USD | 0.0% |
| 2008 | - USD | -100.0% |
| 2007 | 1.48 Million USD | -97.23% |
| 2006 | 53.64 Million USD | -9.7% |
| 2005 | 59.4 Million USD | -10.17% |
| 2004 | 66.12 Million USD | 81.5% |
| 2003 | 36.43 Million USD | 359.14% |
| 2002 | 7.93 Million USD | 39.53% |
| 2001 | 5.68 Million USD | 46.95% |
| 2000 | 3.87 Million USD | 24.84% |
| 1999 | 3.1 Million USD | 3.33% |
| 1998 | 3 Million USD | 87.5% |
| 1997 | 1.6 Million USD | 0.0% |
| 1996 | 1.6 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 291.6 Million USD | -46.68% |
| 2024 Q1 | 546.9 Million USD | 27.66% |
| 2024 Q3 | 251.4 Million USD | -13.79% |
| 2023 Q2 | 258.8 Million USD | -0.42% |
| 2023 Q1 | 259.9 Million USD | -1.14% |
| 2023 Q3 | 255.8 Million USD | -1.16% |
| 2023 FY | 428.4 Million USD | 62.95% |
| 2023 Q4 | 428.4 Million USD | 67.47% |
| 2022 FY | 262.9 Million USD | -40.3% |
| 2022 Q2 | 268.6 Million USD | -44.06% |
| 2022 Q3 | 265.8 Million USD | -1.04% |
| 2022 Q1 | 480.2 Million USD | 9.04% |
| 2022 Q4 | 262.9 Million USD | -1.09% |
| 2021 Q3 | 437.1 Million USD | 0.41% |
| 2021 Q2 | 435.3 Million USD | 1.35% |
| 2021 Q1 | 429.5 Million USD | 4.17% |
| 2021 Q4 | 440.4 Million USD | 0.75% |
| 2021 FY | 440.4 Million USD | 6.82% |
| 2020 Q3 | 508 Million USD | 0.83% |
| 2020 Q1 | 499.7 Million USD | 0.85% |
| 2020 Q2 | 503.8 Million USD | 0.82% |
| 2020 FY | 412.3 Million USD | -16.79% |
| 2020 Q4 | 412.3 Million USD | -18.84% |
| 2019 Q3 | 478.07 Million USD | 2.89% |
| 2019 Q1 | 460.58 Million USD | 18.56% |
| 2019 Q4 | 495.5 Million USD | 3.65% |
| 2019 Q2 | 464.65 Million USD | 0.88% |
| 2019 FY | 495.5 Million USD | 27.54% |
| 2018 Q1 | 374.2 Million USD | 1.24% |
| 2018 FY | 388.49 Million USD | 5.11% |
| 2018 Q4 | 388.49 Million USD | 1.26% |
| 2018 Q3 | 383.64 Million USD | 1.26% |
| 2018 Q2 | 378.88 Million USD | 1.25% |
| 2017 FY | 369.61 Million USD | 0.0% |
| 2017 Q4 | 369.61 Million USD | 1.23% |
| 2017 Q3 | 365.11 Million USD | 1.23% |
| 2017 Q2 | 360.68 Million USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 Q1 | 10.53 Million USD | -8.66% |
| 2010 FY | - USD | -100.0% |
| 2010 Q4 | - USD | -100.0% |
| 2010 Q3 | 8.53 Million USD | -10.57% |
| 2010 Q2 | 9.54 Million USD | -9.39% |
| 2009 Q3 | 17.27 Million USD | -4.89% |
| 2009 Q1 | 18.21 Million USD | 0.0% |
| 2009 Q2 | 18.16 Million USD | -0.3% |
| 2009 FY | 11.53 Million USD | 0.0% |
| 2009 Q4 | 11.53 Million USD | -33.26% |
| 2008 Q2 | 601 Thousand USD | -41.37% |
| 2008 Q3 | 276 Thousand USD | -54.08% |
| 2008 Q4 | - USD | -100.0% |
| 2008 FY | - USD | -100.0% |
| 2008 Q1 | 1.02 Million USD | -31.02% |
| 2007 Q2 | 51.2 Million USD | -2.29% |
| 2007 Q4 | 1.48 Million USD | -97.04% |
| 2007 Q1 | 52.4 Million USD | -2.31% |
| 2007 FY | 1.48 Million USD | -97.23% |
| 2007 Q3 | 50.12 Million USD | -2.1% |
| 2006 Q2 | 56.45 Million USD | -2.59% |
| 2006 Q4 | 53.64 Million USD | -2.46% |
| 2006 FY | 53.64 Million USD | -9.7% |
| 2006 Q1 | 57.95 Million USD | -2.45% |
| 2006 Q3 | 54.99 Million USD | -2.58% |
| 2005 Q3 | 60.99 Million USD | -2.62% |
| 2005 Q4 | 59.4 Million USD | -2.61% |
| 2005 Q2 | 62.63 Million USD | -2.75% |
| 2005 Q1 | 64.4 Million USD | -2.6% |
| 2005 FY | 59.4 Million USD | -10.17% |
| 2004 Q1 | 47.13 Million USD | 29.36% |
| 2004 Q4 | 66.12 Million USD | -3.74% |
| 2004 Q3 | 68.69 Million USD | 16.67% |
| 2004 Q2 | 58.88 Million USD | 24.93% |
| 2004 FY | 66.12 Million USD | 81.5% |
| 2003 Q2 | 22.46 Million USD | 170.62% |
| 2003 Q3 | 22.52 Million USD | 0.27% |
| 2003 Q4 | 36.43 Million USD | 61.73% |
| 2003 FY | 36.43 Million USD | 359.14% |
| 2003 Q1 | 8.3 Million USD | 4.63% |
| 2002 Q3 | 6.68 Million USD | 19.64% |
| 2002 FY | 7.93 Million USD | 39.53% |
| 2002 Q4 | 7.93 Million USD | 18.63% |
| 2002 Q1 | 5.11 Million USD | -10.06% |
| 2002 Q2 | 5.59 Million USD | 9.31% |
| 2001 Q2 | 4.16 Million USD | 18.16% |
| 2001 Q4 | 5.68 Million USD | 52.22% |
| 2001 Q3 | 3.73 Million USD | -10.28% |
| 2001 Q1 | 3.52 Million USD | -8.94% |
| 2001 FY | 5.68 Million USD | 46.95% |
| 2000 Q1 | 2.87 Million USD | -7.29% |
| 2000 Q2 | 2.63 Million USD | -8.39% |
| 2000 FY | 3.87 Million USD | 24.84% |
| 2000 Q3 | 3.05 Million USD | 16.1% |
| 2000 Q4 | 3.87 Million USD | 26.59% |
| 1999 Q1 | 3.6 Million USD | 20.0% |
| 1999 FY | 3.1 Million USD | 3.33% |
| 1999 Q2 | 2.3 Million USD | -36.11% |
| 1999 Q3 | 3.1 Million USD | 34.78% |
| 1999 Q4 | 3.1 Million USD | 0.0% |
| 1998 FY | 3 Million USD | 87.5% |
| 1998 Q1 | 1.2 Million USD | -25.0% |
| 1998 Q4 | 3 Million USD | -6.25% |
| 1998 Q3 | 3.2 Million USD | 88.24% |
| 1998 Q2 | 1.7 Million USD | 41.67% |
| 1997 Q4 | 1.6 Million USD | 45.45% |
| 1997 Q3 | 1.1 Million USD | -8.33% |
| 1997 FY | 1.6 Million USD | 0.0% |
| 1997 Q2 | 1.2 Million USD | 0.0% |
| 1997 Q1 | 1.2 Million USD | -25.0% |
| 1996 FY | 1.6 Million USD | 0.0% |
| 1996 Q4 | 1.6 Million USD | 23.08% |
| 1996 Q1 | 2.2 Million USD | 0.0% |
| 1996 Q2 | - USD | -100.0% |
| 1996 Q3 | 1.3 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 540.94 Million USD | 20.806% |
| Theratechnologies Inc. | 58.96 Million USD | -626.496% |
| Safety Shot Inc | 1.54 Million USD | -27557.017% |
| Cosmos Health Inc. | 12.42 Million USD | -3348.178% |
| Cronos Group Inc. | 2.53 Million USD | -16766.553% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 40.129% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -1079.418% |
| Organogenesis Holdings Inc. | 119.35 Million USD | -258.941% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -7714.016% |
| ProPhase Labs, Inc. | 21.38 Million USD | -1903.742% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -70360.526% |
| Dynavax Technologies Corporation | 256.91 Million USD | -66.748% |
| Radius Health, Inc. | 365.31 Million USD | -17.269% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -16081.578% |
| Alvotech | 1.07 Billion USD | 60.166% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -65035.585% |
| Alpha Teknova, Inc. | 30.45 Million USD | -1306.527% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -2429.224% |
| SCYNEXIS, Inc. | 15.08 Million USD | -2740.849% |
| Harrow Health, Inc. | 190.5 Million USD | -124.88% |
| Biofrontera Inc. | 5.39 Million USD | -7834.803% |
| DURECT Corporation | 20.74 Million USD | -1964.976% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -931.618% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | -35.859% |
| OptiNose, Inc. | 131.74 Million USD | -225.164% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -36421.552% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | -333.507% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -2224.662% |
| SIGA Technologies, Inc. | 1.46 Million USD | -29162.115% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | -228.628% |
| Shineco, Inc. | 29.65 Million USD | -1344.543% |
| Phibro Animal Health Corporation | 525.45 Million USD | 18.471% |
| Procaps Group S.A. | 285.93 Million USD | -49.824% |
| TherapeuticsMD, Inc. | 8 Million USD | -5251.655% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -716204.112% |
| Viatris Inc. | 18.12 Billion USD | 97.636% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -65035.585% |
| Rockwell Medical, Inc. | 13.43 Million USD | -3087.737% |
| Incannex Healthcare Limited | 373 Thousand USD | -114752.547% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -2731.648% |
| Tilray Brands, Inc. | 387.31 Million USD | -10.607% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 36.466% |
| PetIQ, Inc. | 468.3 Million USD | 8.521% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Journey Medical Corporation | 17.73 Million USD | -2316.244% |
| Alimera Sciences, Inc. | 67.39 Million USD | -535.618% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -5076.044% |
| Assertio Holdings, Inc. | 40.91 Million USD | -947.126% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -39286.077% |
| Embecta Corp. | 1.63 Billion USD | 73.854% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -41366.826% |
| Procaps Group, S.A. | 285.93 Million USD | -49.824% |
| PainReform Ltd. | 86 Thousand USD | -498039.535% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | -1110.717% |
| Hempacco Co., Inc. | 13.72 Million USD | -3021.424% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 26.9% |
| Alvotech | 1.07 Billion USD | 60.166% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 30.561% |
| Kamada Ltd. | 8.74 Million USD | -4796.567% |
| Indivior PLC | 281.6 Million USD | -52.13% |
| Currenc Group, Inc. | 31.94 Million USD | -1241.112% |
| Evoke Pharma, Inc. | 5 Million USD | -8468.0% |
| Flora Growth Corp. | 3.67 Million USD | -11566.667% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -41366.826% |
| Evolus, Inc. | 126.54 Million USD | -238.533% |
| HUTCHMED (China) Limited | 86.13 Million USD | -397.382% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 31.307% |
| Akanda Corp. | 3.99 Million USD | -10613.238% |